Cardinal Health report examines shifts in biosimilars industry

The report assesses new and changing perspectives regarding some of the most disruptive biosimilars launched in the last areas of ophthalmology and immunology. (Image Credit: Adobe Stock)

Cardinal Health recently released its 2023 Biosimilars Report: Tracking Market Expansion and Sustainability Amidst a Shifting Industry, a publication that shines a spotlight on provider perceptions, utilization and the latest market trends of biosimilars.

According to the company, the report assesses new and changing perspectives regarding some of the most disruptive biosimilars launched in the areas of ophthalmology and immunology, noting a growing familiarity of the medications among rheumatologists with 76% reporting being very familiar with the products, a 43% jump year-over-year.

The research also reports high familiarity among gastroenterologists (81%) compared to ophthalmologists (33%) and dermatologists (31%).

"Biosimilars bring competition and lower costs to patient-critical treatments,” Bruce Feinberg, chief medical officer and vice president of Cardinal Health, said in the news release. "In order to deliver on the promise of these drugs from a health equity standpoint, we must continue to analyze prescriber awareness and familiarity.”

Through its research, Feinberg pointed out that Cardinal Health seeks to understand prescribers’ perceptions and what other factors are moving the industry forward—from business and financial decisions to provider adoption.

In the study, Cardinal Health surveyed more than 350 providers across ophthalmology, rheumatology, gastroenterology and dermatology. The responses offer new analysis, insights into market growth, drivers of adoption, and obstacles that remain in the market. The new report also includes an updated analysis of biosimilar market adoption and key milestones achieved throughout 2022, and highlights how policy and updated formulary announcements may impact patient access of these critical therapeutics.

In addition to general provider perceptions, this report provides in-depth analysis of how up to 10 Humira (adalimumab) biosimilars launching in 2023 may affect the market with provider input on the most important product attributes for each therapeutic area (e.g. latex and citrate-free solutions).

The 2023 Biosimilars Report also contains:

• A lookback at five key milestones achieved in 2022, including how the Enhancing Oncology Model might continue the growth and adoption of biosimilars in the oncology market
  
  
• A detailed examination of how the Inflation Reduction Act could affect the biosimilars market
  
  
• Commentary from industry stakeholders on the single most critical action needed to ensure a sustainable U.S. biosimilars market
  
  
• An updated pipeline of biosimilars expected to come to market in the next three years
  
  

More details on the report can be accessed at the Cardinal Health website.